What's happening
This bill requires newborn screening for Duchenne muscular dystrophy in New York once a validated test is available.
Why it matters
Early detection of Duchenne muscular dystrophy (DMD) through newborn screening could significantly improve health outcomes. by enabling earlier intervention, access to specialized care, and potential participation in emerging therapies or clinical trials.
The bill places responsibility on the Wadsworth Center to validate a reliable test before implementation, ensuring scientific rigor and accuracy. this safeguards families from the risks of false positives or negatives in a sensitive medical context.
Mandating statewide DMD screening promotes health equity. , as all newborns in New York, regardless of socioeconomic status or hospital location, would have access to this critical diagnostic test once it is available and validated.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Test Newborns for Duchenne
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Substituted by A5042
- Ordered to third reading cal.1766
- Committee discharged and committed to rules
- Reported and committed to finance
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Add Newborn DMD Screening
Signed by Governor · Sponsor Andrew Hevesi
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6814
2023-2024 Regular Sessions
IN SENATE
May 10, 2023
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to newborn screening for duchenne muscular dystrophy
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivision 1 of section 2500-a of the public health law is amended by adding a new subdivision (k) to read as follows:
(k) Duchenne muscular dystrophy using a test validated by the Wadsworth center for laboratories and research.
§ 2. The Wadsworth center for laboratories and research shall undertake the process for testing validation upon the development of a test for duchenne muscular dystrophy.
§ 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD09703-01-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to newborn screening for duchenne muscular dystrophy
Purpose or general idea of bill
This bill adds Duchenne muscular dystrophy to the list of diseases and conditions that newborns are required to be tested for.
Summary of specific provisions
Section 1 of the bill authorizes the Commissioner of Health to add Duch- enne muscular dystrophy to the list of diseases and conditions that every infant under 28 days of age must be tested for once the Wadsworth Center validates such test.
Section 2 of the bill includes the effective date
Justification
Duchenne muscular dystrophy (Duchenne), the most common form of muscular dystrophy, is a fatal genetic pediatric disease that results in progres- sive muscle deterioration and weakness, which causes an inability to walk and feed oneself and to breathe unassisted over time. Duchenne is caused by a gene mutation and affects approximately one out of every 3,500 to 5,000 male births with most patient's dying in their mid-to- late twenties.
The average age for diagnosis of Duchenne is five years of age, which is on average 2.5 years after parents or caregivers typically first notice symptoms of the disease. This diagnosis delay is often worse for fami- lies of color and families of lower socioeconomic status.
Early detection of Duchenne is important as it is a non-reversible progressive disease for which there are currently multiple treatments that significantly slow the progression of the disease, four of which are approved by the U.S. Food and Drug Administration (FDA) for use from the date of birth. Additionally, there are several gene therapies targeting the mutated gene that causes Duchenne that are currently in trials.
Newborn screening for detecting Duchenne is currently available as the FDA has already approved a lab test that uses the same blood spots that are collected at birth. New York currently requires newborn screening for over 50 diseases and conditions including congenital heart defects, adrenoleukodystrophy, hypothyroidism, HIV, and Cystic Fibrosis.
Adding Duchenne to the list of conditions and diseases that are screened for newborns will help identify individuals who should begin receiving appropriate care and treatments sooner and will help eliminate the racial and socioeconomic disparities of diagnosis and treatment of Duch- enne.
Prior legislative history
None
Fiscal implications
None
Effective date
This act shall take effect on the 120th day after it shall become law. Effective immediately, the Commissioner of Health shall make regulations and take other actions reasonably necessary to implement this act on that date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.